Baseline patient and disease characteristics
| N=30 | |
| Sex | |
| Male | 19 (63) |
| Female | 11 (37) |
| Age, years | |
| Median (IQR) | 67 (58–69) |
| ECOG performance status | |
| 0 | 8 (27) |
| 1 | 22 (73) |
| Biliary tract cancer classification | |
| Gallbladder cancer | 12 (40) |
| Intrahepatic cholangiocarcinoma | 10 (33) |
| Extrahepatic cholangiocarcinoma | 7 (23) |
| Ampullary cancer | 1 (3) |
| Number of prior anticancer therapies* | |
| 1 | 26 (87) |
| 2 | 3 (10) |
| 3 | 1 (3) |
| PD-L1 expression† | |
| Positive | 16 (53) |
| Negative | 13 (43) |
| Not evaluable | 1 (3) |
| HBV/HCV positivity | |
| HBsAg | 1 (3) |
| HBsAb | 8 (27) |
| HBcAb | 13 (43) |
| HBV-DNA | 0 |
| HCV Ab | 0 |
| Immune phenotype status | |
| Immune-desert | 3 (10) |
| Immune-excluded | 23 (77) |
| Inflamed | 2 (7) |
| Not evaluable | 2 (7) |
Data are n (%) unless otherwise specified.
Positive: PD-L1 expression in ≥1% of tumor cells; negative: PD-L1 expression in <1% of tumor cells.
*Include neoadjuvant and adjuvant therapies.
†Defined as the proportion of tumor cells showing membranous PD-L1 staining.
HCV Ab, antibody [NOTE: THIS IS PUTTING HCV Ab IN PROOF. SHOULD BE: "Ab, antibody"]; ECOG, Eastern Cooperative Oncology Group; HBcAb, hepatitis B virus core antibody; HBsAb, hepatitis B virus surface antibody; HBsAg, hepatitis B virus surface antigen; HBV, hepatitis B virus; HBV-DNA, hepatitis B virus DNA; HCV, hepatitis C virus; PD-L1, programmed death ligand 1.